Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
Chemotherapy Induced Nausea and Vomiting
Primary: Feasibility of Recruitment and Data Collection. — 70.4 percentage of completed forms
Phase 2 N=10 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Breast Cancer
Primary: Clinical Benefit Rate — 0; 0; 3; 7 Participants
Phase 2 N=16 Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
Sleep Apnea, Obstructive
Primary: Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility — -5.2; -1.9; -2.2; -0.7 cm H2O — p=0.049
Phase 2 N=15 A Study of Pregnenolone in the Treatment of Individuals With Autism
Autistic Disorder
Primary: Number of Participants With Adverse Events According to Dosage Record and Treatment Emergent Symptom (DOTES) as Assessed at All Follow-up Visits (2, 4, 6, 8, 10, 12, and…
Phase 2 N=50 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…
Phase 2 N=24 An Open-Label Study of N-Acetyl Cysteine in Children With Autism
Autistic Disorder
Primary: Number of Participants With Adverse Events Reported on the Dosage Record and Treatment Emergent Symptom Scale (DOTES) — 17 number of participants
Phase 2 N=68 Medication Development in Alcoholism: Acamprosate Versus Naltrexone
Alcoholism
Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period — 2.12; 3.40; 5.86…
Phase 2 N=80 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Adult Glioblastoma Multiforme
Primary: Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6) — 12.5; 7.5 percentage of participants
Phase 2 N=17 Celecoxib as a Post-tonsillectomy Pain Medication
Tonsillitis
Primary: Self-reported Pain Score — 5.0; 6.0; 5.1; 6.0 pain score (units on a scale) — p=.674
Phase 2 N=136 Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Prostate Cancer
Primary: Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 events
Phase 2 N=31 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 — 0 Participants
Phase 2 N=58 Pre-Exposure Prophylaxis in YMSM
HIV
Primary: Actual Number of Study Visits Completed by 24 Weeks — 3.5927; 4.6263; 4.6374 Visits — p=0.6983
Phase 2 N=14 Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting
Blood Transfusion · Endothelial Physiopathology · Nitric Oxide
Primary: Systolic Pulmonary Artery Pressure — 39; 46; 31 mmHg
Phase 2 N=31 A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
Epilepsy
Primary: Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax), — 208; 23.9 nanogram/milliliter (ng/mL)